Targeted Delivery of Proteins Using Engineered Extracellular Vesicles
Author Information
Author(s): Leyla A. Ovchinnikova, Daria Y. Tanygina, Samir S. Dzhelad, Evgeniy G. Evtushenko, Dmitriy V. Bagrov, Alexander G. Gabibov, Yakov A. Lomakin
Primary Institution: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia
Hypothesis
Can engineered extracellular vesicles (EVs) specifically deliver proteins to CD206-positive antigen-presenting cells?
Conclusion
The study demonstrates that nanobody-functionalized EVs enhance the delivery of proteins to CD206-positive cells compared to non-targeted EVs.
Supporting Evidence
- Nanobody-functionalized EVs showed enhanced interaction with CD206+ cells.
- Replacing full-length VSV-G with a truncated form improved specificity of EV uptake.
- Engineered EVs were characterized using nanoparticle tracking analysis and size exclusion chromatography.
Takeaway
Scientists created special tiny bubbles called extracellular vesicles that can deliver medicine directly to specific immune cells, helping the body fight diseases better.
Methodology
The study involved engineering extracellular vesicles to display anti-CD206 nanobodies and testing their ability to deliver proteins to activated human antigen-presenting cells.
Limitations
Further investigation is needed to explore the effectiveness of engineered EVs with other immunogenic antigens and the high production costs.
Participant Demographics
Healthy human donors provided peripheral blood mononuclear cells for the study.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website